Literature DB >> 27377970

A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.

Alexey V Danilov1, Lionel D Lewis2, Frederick Lansigan2, Liya Roudaia2, Darcie L Findley2, Susan Y Jones2, Brian Highhouse2, Bernard B Beaulieu2, Jennifer R Brown3.   

Abstract

Entities:  

Keywords:  bendamustine; chronic lymphocytic leukaemia; comorbidities

Mesh：

Substances：

Year:  2016        PMID： 27377970      PMCID： PMC5215978          DOI： 10.1111/bjh.14171

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century.

Authors:  Hermann Brenner; Adam Gondos; Dianne Pulte
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

3.  Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.

Authors:  Paul Thurmes; Timothy Call; Susan Slager; Clive Zent; Gregory Jenkins; Susan Schwager; Deborah Bowen; Neil Kay; Tait Shanafelt
Journal:  Leuk Lymphoma       Date:  2008-01

4.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

5.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors:  Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

6.  A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients.

Authors:  Fabio Salvi; Mark D Miller; Annalisa Grilli; Raffaella Giorgi; Adele L Towers; Valeria Morichi; Liana Spazzafumo; Lucia Mancinelli; Emma Espinosa; Alessandro Rappelli; Paolo Dessì-Fulgheri
Journal:  J Am Geriatr Soc       Date:  2008-09-22       Impact factor: 5.562

7.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Kirsten Fischer; Paula Cramer; Raymonde Busch; Sebastian Böttcher; Jasmin Bahlo; Jöerg Schubert; Karl H Pflüger; Silke Schott; Valentin Goede; Susanne Isfort; Julia von Tresckow; Anna-Maria Fink; Andreas Bühler; Dirk Winkler; Karl-Anton Kreuzer; Peter Staib; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Barbara F Eichhorst; Michael Hallek; Stephan Stilgenbauer; Clemens-Martin Wendtner
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.

Authors:  M Rasschaert; D Schrijvers; J Van den Brande; J Dyck; J Bosmans; K Merkle; J B Vermorken
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640
  8 in total
  1 in total

1.  Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia.

Authors:  Irene Dogliotti; Simone Ragaini; Francesco Vassallo; Elia Boccellato; Gabriele De Luca; Francesca Perutelli; Carola Boccomini; Michele Clerico; Barbara Botto; Daniele Grimaldi; Lorella Orsucci; Simone Ferrero; Candida Vitale; Dario Ferrero; Marta Coscia; Federica Cavallo
Journal:  J Pers Med       Date:  2021-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.